Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced significant hair regrowth with topical finasteride, minoxidil, ketoconazole, and dermarolling, but later faced severe hair shedding after stopping dermarolling and reducing ketoconazole use. Suggestions included switching to oral treatments, resuming dermarolling, and considering lifestyle changes.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

A user discusses an Iranian hair loss treatment brought by their mom, questioning its effectiveness. Replies mention that Kopexil, an ingredient in the product, is different from Minoxidil and less tested.

A 30-year-old woman with androgenetic alopecia is considering bicalutamide to slow hair loss but is concerned about its impact on muscle growth due to its anti-androgen effects. Alternatives suggested include dutasteride, spironolactone, RU58841, and minoxidil, with concerns about bicalutamide's side effects.

Cosmo Pharmaceuticals has enrolled about 850 out of 1400 patients for their phase 3 clinical trials of clascoterone (Breezula) and claims to be on schedule. The conversation is about hair loss treatments.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

The user is experiencing hair loss, initially diagnosed as Telogen Effluvium due to stress, but is concerned it might be Androgenetic Alopecia (AGA). A suggestion was made to consider using Minoxidil or Finasteride if the condition worsens.

A user shared a 10-month update on their hair loss treatment, including a hair transplant of 2300 grafts and 7.5 months of using a topical minoxidil/finasteride solution and ketoconazole shampoo. They expressed regret for not starting the medications sooner and reported side effects like heart palpitations, which improved after cutting out caffeine.

The conversation is about a person using minoxidil, finasteride, estrogen, and bicalutamide to combat hair loss, expressing frustration and desperation over their situation. They are advised against using female hormones and encouraged to focus on finasteride and minoxidil, with suggestions to seek therapy for mental health support.

Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.

The conversation is about someone looking for specific side effects reported in clinical trials for GT20029, a hair loss treatment. No results or data were found on the clinical trials site.

The user is using RU58841, finasteride, dutasteride, and minoxidil to slow down aggressive hair loss but is still experiencing hair shedding due to high testosterone levels. They plan to use ostarine to lower testosterone and prevent hair loss while maintaining muscle mass, and will continue using the other treatments.

A user humorously suggests an extreme hair loss treatment regimen involving multiple medications and therapies, including Dutasteride, Minoxidil, RU58841, and others, claiming it would prevent hair loss but with potential side effects like gynecomastia. The conversation highlights concerns about safety, side effects, and the effectiveness of such a comprehensive approach.

KX826 shows promise as a hair loss treatment with a 10% increase in hair count, but concerns about Kintor's marketing practices and the systemic effects of treatments like GT20029 and RU58841 remain. Users express skepticism and hope, with some preferring traditional treatments like finasteride and minoxidil.

User discusses Alfatradiol (17a-Estradiol) as a potential hair loss treatment with mixed results. Concerns include low dosage, receptor theory, and possible increased aromatase activity on scalp.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

A transgender woman experienced significant hair regrowth after 18 months of hormone replacement therapy (HRT) with estrogen and bicalutamide. The discussion notes HRT's effectiveness for hair regrowth but warns against its use for cisgender men due to feminizing effects.

The user plans to use 1% Koshine826, 0.1% Alfatradiol, Minoxidil with Tretinoin, microneedling, and Stemoxydine for hair loss treatment. They expect significant recovery with this regimen.

The conversation discusses whether gt20029 could cure complete baldness, mentioning verteporfin as a realistic treatment. Other treatments like Minoxidil, finasteride, and RU58841 are implied to be less promising.

The user discusses their experience with hair loss despite taking estrogen and cyproterone, and estimates needing around 3000 grafts for a feminine hairline. They are considering getting the procedure done in Turkey due to high European costs.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

Clascoterone lotion, being tested in Germany, is as effective as Minoxidil and Finasteride for hair loss but without serious side effects. About 400 men participated in the trials.

Cassiopea claimed that their hair loss treatment, Clascoterone, shows comparable results to finasteride after six months of use. Some users believe Clascoterone could be an additional treatment option for those who do not respond to finasteride.

Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

PP405, a potential hair loss treatment, is facing delays in releasing Phase 2 results, causing frustration among users who compare it to past failed treatments. Despite skepticism, some remain hopeful about PP405's future, while others discuss alternative treatments like Clascoterone and its expected market release.

A 12-year-old diagnosed with alopecia shares their experience and current treatments, including Dermovate, an unnamed cream, and liquid iron. The community offers support and encouragement.

The conversation discusses potential causes of pigmentation around hair follicles, suggesting sebum buildup, autoimmune conditions, or dermatitis. Treatments mentioned include finasteride, dutasteride, and an anti-inflammatory diet, with a recommendation to consult a doctor for a proper diagnosis.

The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.